Latest On Champions Oncology, Inc (CSBR):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2023-03-17 22:49 EST | News | Champions Oncology, Inc. (CSBR) Q3 2023 Earnings Call Transcript | N/A |  |
| 2023-03-16 01:23 EST | News | Champions Oncology Non-GAAP EPS of -$0.16 misses by $0.15, revenue of $12.77M misses by $0.36M | N/A | |
| 2023-01-29 10:36 EST | News | Champions Oncology Trades At A Sufficient Discount To R&D Capacity | N/A | |
| 2022-12-13 22:00 EST | News | Champions Oncology Non-GAAP EPS of $0.01 misses by $0.01, revenue of $14.28M beats by $0.34M | N/A | |
| 2022-12-13 22:00 EST | News | Champions Oncology, Inc. (CSBR) Q2 2023 Earnings Call Transcript | N/A | |
| 2022-09-09 20:30 EST | News | Champions Oncology, Inc. (CSBR) Q1 2023 Earnings Call Transcript | N/A | |
| 2022-09-09 03:14 EST | News | Champions Oncology GAAP EPS of -$0.02 misses by $0.03, revenue of $13.7M beats by $0.51M | N/A | |
| 2022-07-22 14:12 EST | News | Champions Oncology Non-GAAP EPS of -$0.02, revenue of $12.9M | N/A | |
| 2022-03-17 06:01 EST | News | Champions Oncology's (CSBR) CEO Ronnie Morris on Q3 2022 Results - Earnings Call Transcript | N/A | |
| 2022-03-15 20:57 EST | News | Champions Oncology Non-GAAP EPS of $0.07, revenue of $13.2M | N/A | |
| 2022-02-15 22:05 EST | News | Champions Oncology, GigaMune collaborate on next-gen T cell therapies | N/A | |
| 2022-01-20 18:00 EST | News | Champions Oncology-Fannin team up to develop therapeutics for tumors | N/A | |
| 2021-12-14 12:41 EST | News | Champions Oncology Inc.'s (CSBR) CEO Ronnie Morris on Q2 2022 Results - Earnings Call Transcript | N/A | |
| 2021-12-13 17:57 EST | News | Champions Oncology EPS beats by $0.02, beats on revenue | N/A | |
| 2021-11-26 14:58 EST | News | Warning: CSBR is at high risk of performing badly | N/A | |
| 2021-09-21 15:35 EST | News | Champions Oncology EPS in-line, beats on revenue | N/A | |
| 2021-09-21 15:33 EST | News | Champions Oncology's (CSBR) CEO Ronnie Morris on Q1 FY2022 Results - Earnings Call Transcript | N/A | |
| 2021-03-27 02:03 EST | News | Champions Oncology (CSBR) Investor Presentation - Slideshow | N/A | |
| 2021-03-16 20:34 EST | Analyst Rating | The Analyst Target Price has increased from $13.83 to $15. | Buy | |
| 2021-03-12 11:25 EST | Financials | Company financials have been released. | Neutral | |
| 2021-03-12 03:28 EST | Earnings Estimate | An EPS average of $0.01 is estimated for the quarter ending on July 31, 2021. | Sell | |
| 2021-03-12 02:02 EST | News | Champions Oncology EPS beats by $0.04, beats on revenue | N/A | |
| 2021-01-20 01:57 EST | News | Champions Oncology partners with Code Ocean, expanding functionality of Lumin Bioinformatics | N/A | |
| 2020-12-17 03:29 EST | Analyst Rating | The Analyst Target Price has increased from $12.83 to $13.83. | Buy | |
| 2020-12-16 03:35 EST | Analyst Rating | The Analyst Target Price has increased from $11 to $12.83. | Buy | |
| 2020-12-15 11:35 EST | Financials | Company financials have been released. | Neutral | |
| 2020-12-14 17:12 EST | News | Champions Oncology beats on revenue | N/A | |
| 2020-12-13 03:43 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-07 15:31 EST | Financials | Company financials have been released. | Neutral | |
| 2020-10-30 17:04 EST | Insider Trade | SCOTT R TOBIN has directly acquired 10,000 shares and currently holds 10,000 shares. | Buy | |
| 2020-10-30 08:57 EST | Insider Trade | DAVID SIDRANSKY has directly acquired 16,667 shares and currently holds 758,334 shares. | Buy | |
| 2020-09-26 12:27 EST | Financials | Company financials have been released. | Neutral | |
| 2020-09-17 04:35 EST | Financials | Company financials have been released. | Neutral | |
| 2020-09-16 16:54 EST | News | Champions Oncology +9.8% on FQ1 earnings beat | N/A | |
| 2020-09-16 08:26 EST | Financials | Company financials have been released. | Neutral | |
| 2020-09-15 12:32 EST | Earnings Estimate | An EPS average of $0.03 is estimated for the quarter ending on January 31, 2021. | Buy | |
| 2020-09-15 11:55 EST | News | Champions Oncology EPS beats by $0.01, beats on revenue | N/A | |
| 2020-09-15 11:55 EST | News | Champions Oncology, Inc. (CSBR) CEO Ronnie Morris on Q1 2021 Results - Earnings Call Transcript | N/A | |
| 2020-09-05 00:31 EST | Financials | Company financials have been released. | Neutral | |
| 2020-08-31 12:24 EST | Financials | Company financials have been released. | Neutral | |
| 2020-08-06 20:29 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-31 00:40 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-29 20:33 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-29 12:28 EST | Earnings Estimate | An EPS average of $0.02 is estimated for the quarter ending on October 31, 2020. | Buy | |
| 2020-07-29 12:28 EST | Analyst Rating | The Analyst Target Price has increased from $10.33 to $11. | Buy | |
| 2020-07-28 19:16 EST | News | Champions Oncology slumps on Q4 reports | N/A | |
| 2020-07-28 12:31 EST | Earnings Estimate | An EPS average of $0.30 is estimated for the 2022 year. | Buy | |
| 2020-07-27 19:41 EST | News | Champions Oncology EPS misses by $0.18, beats on revenue | N/A | |
| 2020-07-27 19:40 EST | News | Champions Oncology, Inc. (CSBR) CEO Ronnie Morris on Q4 2020 Results - Earnings Call Transcript | N/A | |
| 2020-07-23 16:43 EST | Financials | Company financials have been released. | Neutral | |
About Champions Oncology, Inc (CSBR):
Champions Oncology, Inc. develops and sells technology solutions and products to personalize the development and use of oncology drugs in the United States. Its Tumorgraft Technology Platform is an approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. The company, through its Tumorgraft Technology Platform, provides Personalized Oncology Solutions (POS) that assist physicians in developing personalized treatment options for cancer patients through tumor specific data obtained from drug panels and related personalized oncology services. It also offers Translational Oncology Solutions that utilizes its technology platform to assist pharmaceutical and biotechnology companies with their drug development process. In addition, the company provides POS products, including TumorGraft implants and drug panels, which utilizes TumorGraft technology to test the response of a patient's tumor to multiple oncology drugs or drug combinations. It markets its products through internet, word of mouth, and sales force to patients and physicians. The company was formerly known as Champions Biotechnology, Inc. and changed its name to Champions Oncology, Inc. in April 2011. Champions Oncology, Inc. was incorporated in 1985 and is headquartered in Hackensack, New Jersey.
General
- Name Champions Oncology, Inc
- Symbol CSBR
- Type Common Stock
- Exchange NASDAQ
- Currency USD
- Country USA
- SectorHealthcare
- IndustryBiotechnology
- Full Time Employees 143
- Last Split Factor1:12
- Last Split Date2015-08-12
- Fiscal Year EndApril
- IPO Date2003-01-10
- Gic SectorHealth Care
- Gic GroupPharmaceuticals, Biotechnology & Life Sciences
- Gic IndustryLife Sciences Tools & Services
- Gic SubIndustryLife Sciences Tools & Services
- Web URLhttp://www.championsoncology.com
View More
Valuation
- Forward PE 71.43
- Price/Sales (Trailing 12 Mt.) 4.09
- Price/Book (Most Recent Quarter) 21.26
- Enterprise Value Revenue 4.24
- Enterprise Value EBITDA 481.86
View More
Financials
- Most Recent Quarter 2021-01-31
- Current Year EPS Estimate $0.06
- Next Year EPS Estimate $0.20
- Profit Margin -3%
- Operating Margin -2%
- Return on Assets -2%
- Return on Equity -22%
- Revenue 39.22 million
- Earnings Per Share -$0.09
- Revenue Per Share $3.06
- Gross Profit 15.24 million
- Quarterly Earnings Growth 20%
View More
Highlights
- Market Capitalization 176.75 million
- EBITDA 345000
- Analyst Target Price $15
- Book Value Per Share $0.59
View More
Share Statistics
- Shares Outstanding 13.39 million
- Shares Float 6.55 million
- % Held by Insiders 2055%
- % Held by Institutions 53.79%
- Shares Short 153791
- Shares Short Prior Month 140204
- Short Ratio 5.87
- Short % of Float 3%
- Short % of Shares Outstanding 1%
View More
Technicals
- Beta 1.23
- 52 Week High $14.68
- 52 Week Low $4.84
- 50 Day Moving Average 11.69
- 200 Day Moving Average 10.46
View More
Dividends
- Dividend Date N/A
- ExDividend Date N/A
- Dividend Yield 0%
View More
Champions Oncology, Inc (CSBR) Dividend Calendar:
| Ex-Dividend Date | Payment Date | Record Date | Declared Date | Amount |
|---|
Champions Oncology, Inc (CSBR) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
| Quarter Date | Report Date | Actual Revenue | Reported EPS | EPS Estimate | Deviation from Estimate |
|---|---|---|---|---|---|
| 2021-01-31 | 2021-03-10 | $N/A | $0.05 | $0.01 | 400% |
| 2020-10-31 | 2020-12-14 | $N/A | $0.00 | $0.01 | -98% |
| 2020-07-31 | 2020-09-14 | $9.55 million | $0.01 | $0.01 | 0% |
| 2020-04-30 | 2020-07-27 | $N/A | -$0.17 | $0.02 | -1233.33% |
| 2020-01-31 | 2020-03-12 | $9.01 million | $0.03 | $0.03 | 20% |
| 2019-10-31 | 2019-12-16 | $7.63 million | $0.02 | -$0.03 | 166.67% |
| 2019-07-31 | 2019-09-16 | $6.74 million | -$0.06 | $0.03 | -300% |
| 2019-04-30 | 2019-07-15 | $7.72 million | -$0.02 | $0.03 | -166.67% |
| 2019-01-31 | 2019-03-18 | $6.43 million | -$0.03 | $0.02 | -228.76% |
| 2018-10-31 | 2018-12-17 | $6.69 million | $0.02 | $0.04 | -50% |
| 2018-07-31 | 2018-09-13 | $6.23 million | $0.04 | $0.01 | 300% |
| 2018-04-30 | 2018-07-26 | $4.92 million | -$0.06 | -$0.04 | -71.43% |
| 2018-01-31 | 2018-03-15 | $5.08 million | -$0.01 | ||
| 2017-10-31 | 2017-12-07 | $5.2 million | -$0.01 | ||
| 2017-07-31 | 2017-09-14 | $5.03 million | -$0.06 | ||
| 2017-04-30 | 2017-07-28 | $3.72 million | -$0.22 | ||
| 2017-01-31 | 2017-03-17 | $3.57 million | -$0.13 | ||
| 2016-10-31 | 2016-12-14 | $4.46 million | -$0.05 | ||
| 2016-07-31 | 2016-09-14 | $3.67 million | -$0.26 | ||
| 2016-04-30 | 2016-07-29 | $2.84 million | -$0.30 | ||
| 2016-01-31 | 2016-01-31 | $2.55 million | -$0.28 | ||
| 2015-10-31 | 2015-10-31 | $2.97 million | -$0.29 | ||
| 2015-07-31 | 2015-07-31 | $2.82 million | -$0.33 | ||
| 2015-04-30 | 2015-04-30 | $3.24 million | -$0.43 | ||
| 2015-01-31 | 2015-01-31 | $1.83 million | -$0.61 | ||
| 2014-10-31 | 2014-10-31 | $1.88 million | -$0.65 | ||
| 2014-07-31 | 2014-07-31 | $1.91 million | -$0.64 | ||
| 2014-04-30 | 2014-04-30 | $2.46 million | -$0.41 | ||
| 2014-01-31 | 2014-01-31 | $3.69 million | -$0.10 | ||
| 2013-10-31 | 2013-10-31 | $2.38 million | -$0.42 | ||
| 2013-07-31 | 2013-07-31 | $3.02 million | -$0.40 | ||
| 2013-04-30 | 2013-04-30 | $1.84 million | -$0.47 | ||
| 2013-01-31 | 2013-01-31 | $2.92 million | -$0.25 | ||
| 2012-10-31 | 2012-10-31 | $1.46 million | -$0.50 | ||
| 2012-07-31 | 2012-07-31 | $2.11 million | -$0.34 | ||
| 2012-04-30 | 2012-04-30 | $1.38 million | -$0.65 | ||
| 2012-01-31 | 2012-01-31 | $2.4 million | -$0.44 | ||
| 2011-10-31 | 2011-10-31 | $1.74 million | -$0.60 | ||
| 2011-07-31 | 2011-07-31 | $1.63 million | -$0.53 | ||
| 2011-04-30 | 2011-04-30 | $1.54 million | -$0.90 | ||
| 2011-01-31 | 2011-02-15 | $2.81 million | -$0.14 | ||
| 2010-10-31 | 2010-11-15 | $933000 | -$0.02 | ||
| 2010-07-31 | 2010-08-15 | $1.6 million | -$0.20 | ||
| 2010-04-30 | 2010-05-15 | $1.9 million | -$0.20 | ||
| 2010-01-31 | 2010-02-15 | $742000 | -$0.28 | ||
| 2009-10-31 | 2009-11-15 | $1.29 million | -$0.21 | ||
| 2009-07-31 | 2009-08-15 | $962000 | -$0.37 | ||
| 2009-04-30 | 2009-05-15 | $1.01 million | -$0.48 | ||
| 2009-01-31 | 2009-01-31 | $983000 | -$0.22 | ||
| 2008-10-31 | 2008-10-31 | $1.04 million | -$0.08 | ||
| 2008-07-31 | 2008-07-31 | $673000 | -$0.05 | ||
| 2008-04-30 | 2008-04-30 | $525000 | -$0.11 | ||
| 2008-01-31 | 2008-01-31 | $625000 | $0.11 | ||
| 2007-10-31 | 2007-10-31 | $-250000 | -$0.06 | ||
| 2007-07-31 | 2007-07-31 | $250000 | $0.00 | ||
| 2007-04-30 | 2007-05-15 | $N/A | -$0.06 | ||
| 2007-01-31 | 2007-02-15 | $N/A | -$0.02 | ||
| 2006-10-31 | 2006-11-15 | $N/A | -$0.03 | ||
| 2006-07-31 | 2006-08-15 | $N/A | -$0.01 | ||
| 2006-04-30 | 2006-05-15 | $N/A | $0.00 | ||
| 2006-01-31 | 2006-02-15 | $N/A | $0.02 | ||
| 2005-10-31 | 2005-11-15 | $N/A | -$0.03 | ||
| 2005-07-31 | 2005-08-15 | $N/A | -$0.17 | ||
| 2005-04-30 | 2005-04-30 | $1.79 million | $0.01 | ||
| 2005-01-31 | 2005-01-31 | $N/A | -$0.06 | ||
| 2004-10-31 | 2004-10-31 | $N/A | -$0.02 | ||
| 2004-07-31 | 2004-08-15 | $N/A | -$0.04 | ||
| 2004-04-30 | 2004-05-15 | $538000 | $0.01 | ||
| 2002-10-31 | 2002-10-31 | $551000 | $0.03 | ||
| 2000-01-31 | 2000-01-31 | $474000 | $0.05 | ||
| 1999-01-31 | 1999-01-31 | $0.07 |
Champions Oncology, Inc (CSBR) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date | Jan 31 2021 | Oct 31 2020 | Jul 31 2020 | Apr 30 2020 | Feb 29 2020 |
|---|---|---|---|---|---|
| Research Development | N/A | N/A | 1.6 million | N/A | 1.82 million |
| Income Before Tax | N/A | N/A | 88000 | N/A | -1.96 million |
| Selling General Administrative | N/A | N/A | 2.59 million | N/A | 3.58 million |
| Gross Profit | N/A | N/A | 4.21 million | N/A | 3.82 million |
| Ebit | N/A | N/A | 301000 | N/A | -1.33 million |
| Operating Income | N/A | N/A | 24000 | N/A | -1.58 million |
| Income Tax Expense | 15000 | 15000 | N/A | 92000 | 92000 |
| Total Revenue | N/A | N/A | 9.55 million | N/A | 8.75 million |
| Cost of Revenue | N/A | N/A | 5.34 million | N/A | 4.92 million |
| Total Other Income Expense Net | N/A | N/A | 64000 | N/A | -378000 |
| Net Income From Continuing Operations | N/A | N/A | 75000 | N/A | -2.05 million |
| Net Income Applicable to Common Shares | 740000 | 1000 | N/A | -2.05 million | -2.05 million |
Cash Flow:
| Date | Oct 31 2020 | Jul 31 2020 | Apr 30 2020 | Feb 29 2020 | Jan 31 2020 |
|---|---|---|---|---|---|
| Investments | N/A | -626000 | N/A | -1.53 million | N/A |
| Change to Liabilities | 1.55 million | N/A | 2.47 million | 2.47 million | 217000 |
| Total Cash Flow from Investing Activities | -506000 | N/A | -1.53 million | -1.53 million | -171000 |
| Net Borrowings | -57000 | N/A | 16000 | 16000 | -37000 |
| Total Cash Flow from Financial Activities | N/A | -58000 | N/A | 4.04 million | 390000 |
| Change to Operating Activities | -293000 | N/A | 1.55 million | 1.55 million | -652000 |
| Change in Cash | N/A | -1.4 million | N/A | 5.06 million | 498000 |
| Total Cash from Operating Activities | 879000 | -715000 | 2.55 million | 2.55 million | 279000 |
| Depreciation | N/A | 277000 | N/A | 246000 | 219000 |
| Other Cash Flow from Investing Activities | N/A | N/A | N/A | N/A | N/A |
| Change to Inventory | N/A | N/A | N/A | N/A | N/A |
| Change to Account Receivables | N/A | -263000 | N/A | -336000 | -425000 |
| Other Cash Flow from Financing Activities | N/A | N/A | N/A | N/A | N/A |
| Change to Net Income | 286000 | N/A | 661000 | 661000 | 514000 |
| Capital Expenditures | N/A | 718000 | N/A | 1.53 million | 171000 |
Balance Sheet:
| Date | Jan 31 2021 | Oct 31 2020 | Jul 31 2020 | Apr 30 2020 | Feb 29 2020 |
|---|---|---|---|---|---|
| Total Liabailities | N/A | N/A | 17.31 million | N/A | N/A |
| Total Stockholder Equity | N/A | N/A | 5.51 million | N/A | N/A |
| Other Current Liabilities | 6.62 million | 6.19 million | N/A | N/A | 5.32 million |
| Total Assets | N/A | N/A | 22.82 million | N/A | N/A |
| Common Stock | 7.87 million | 13000 | N/A | 13000 | N/A |
| Other Current Assets | 419000 | N/A | N/A | N/A | 13000 |
| Retained Earnings | N/A | -72.6 million | -72.6 million | -72.67 million | -72.67 million |
| Other Liabilities | 181000 | 181000 | N/A | 178000 | 178000 |
| Other Assets | 36000 | 36000 | N/A | 128000 | 128000 |
| Cash | N/A | N/A | 6.94 million | N/A | 8.34 million |
| Total Current Liabilities | 11.41 million | 12.75 million | 11.09 million | N/A | 12.09 million |
| Other Stockholder Equity | N/A | N/A | N/A | N/A | N/A |
| Property, Plant & Equipment | 10.92 million | 10.4 million | N/A | 6.79 million | 6.79 million |
| Total Current Assets | 13.97 million | 14.99 million | 12.34 million | N/A | 13.5 million |
| Long Term Investments | N/A | N/A | N/A | N/A | N/A |
| Net Tangible Assets | 7.53 million | 6.56 million | N/A | 4.98 million | 4.98 million |
| Short Term Investments | N/A | N/A | N/A | N/A | N/A |
| Long Term Debt | N/A | N/A | N/A | N/A | N/A |
| Inventory | N/A | N/A | N/A | N/A | N/A |
| Accounts Payable | 4.17 million | 3.95 million | 2.68 million | N/A | 3.14 million |
Champions Oncology, Inc (CSBR) Chart:
Champions Oncology, Inc (CSBR) News:
Below you will find a list of latest news for Champions Oncology, Inc (CSBR) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
Champions Oncology, Inc (CSBR) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
| Expiration Date | Strike | Last Price | Type | Volume | Open Interest | Implied Volatility | In The Money | Change | Change Percent |
|---|---|---|---|---|---|---|---|---|---|
| 2025-02-21 | 2.5 | 0 | CALL | 0 | 0 | 136.97 | TRUE | 0 | 0 |
| 2025-02-21 | 5 | 0 | CALL | 0 | 0 | 202.06 | FALSE | 0 | 0 |
| 2025-02-21 | 7.5 | 0 | CALL | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2025-02-21 | 10 | 0 | CALL | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2025-02-21 | 2.5 | 0.2 | PUT | 0 | 1 | 0 | FALSE | 0 | 0 |
| 2025-02-21 | 5 | 0 | PUT | 0 | 0 | 69.59 | TRUE | 0 | 0 |
| 2025-02-21 | 7.5 | 0 | PUT | 0 | 0 | 124.5 | TRUE | 0 | 0 |
| 2025-02-21 | 10 | 0 | PUT | 0 | 0 | 145.73 | TRUE | 0 | 0 |
| 2025-05-16 | 2.5 | 0 | CALL | 0 | 0 | 113.72 | TRUE | 0 | 0 |
| 2025-05-16 | 5 | 0 | CALL | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2025-05-16 | 7.5 | 0 | CALL | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2025-05-16 | 10 | 0 | CALL | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2025-05-16 | 2.5 | 0 | PUT | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2025-05-16 | 5 | 1.3 | PUT | 2 | 0 | 79.33 | TRUE | 1.3 | 0 |
| 2025-05-16 | 7.5 | 0 | PUT | 0 | 0 | 83.18 | TRUE | 0 | 0 |
| 2025-05-16 | 10 | 0 | PUT | 0 | 0 | 85.08 | TRUE | 0 | 0 |
Latest CSBR Trades:
| Date | Shares | Price |
|---|---|---|
| Jun 13, 2022 4:07 PM EST | 100 | $7.3 |
| Jun 13, 2022 4:08 PM EST | 100 | $7.31 |
| Jun 13, 2022 4:08 PM EST | 100 | $7.3 |
Champions Oncology, Inc (CSBR) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | Form Name | Link |
|---|---|---|---|
| 2020-03-30 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/771856/000162828020004386/0001628280-20-004386-index.htm |
| 2017-01-13 | SC 13D | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/771856/000114036117001769/0001140361-17-001769-index.htm |
| 2017-08-08 | SC 13D/A | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/771856/000114036117030547/0001140361-17-030547-index.htm |
| 2016-11-03 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/771856/000114420416131340/0001144204-16-131340-index.htm |
| 2016-11-03 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/771856/000114420416131342/0001144204-16-131342-index.htm |
| 2019-04-30 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/771856/000117911019005296/0001179110-19-005296-index.htm |
| 2020-03-12 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/771856/000117911020003543/0001179110-20-003543-index.htm |
| 2020-10-30 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/771856/000117911020010718/0001179110-20-010718-index.htm |
| 2016-10-28 | SC 13D/A | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/771856/000119312516751759/0001193125-16-751759-index.htm |
| 2020-03-10 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/771856/000120919120017699/0001209191-20-017699-index.htm |
| 2016-11-01 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/771856/000162828016020505/0001628280-16-020505-index.htm |
| 2016-11-01 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/771856/000162828016020507/0001628280-16-020507-index.htm |
| 2016-11-01 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/771856/000162828016020509/0001628280-16-020509-index.htm |
| 2016-11-03 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/771856/000162828016020689/0001628280-16-020689-index.htm |
| 2016-11-03 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/771856/000162828016020690/0001628280-16-020690-index.htm |
| 2016-11-16 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/771856/000162828016021506/0001628280-16-021506-index.htm |
| 2016-11-16 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/771856/000162828016021508/0001628280-16-021508-index.htm |
| 2016-11-29 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/771856/000162828016021707/0001628280-16-021707-index.htm |
| 2016-12-14 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/771856/000162828016022031/0001628280-16-022031-index.htm |
| 2017-01-26 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/771856/000162828017000428/0001628280-17-000428-index.htm |
| 2017-03-10 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/771856/000162828017002464/0001628280-17-002464-index.htm |
| 2017-03-16 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/771856/000162828017002637/0001628280-17-002637-index.htm |
| 2017-03-17 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/771856/000162828017002681/0001628280-17-002681-index.htm |
| 2017-04-28 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/771856/000162828017004475/0001628280-17-004475-index.htm |
| 2017-05-09 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/771856/000162828017005232/0001628280-17-005232-index.htm |
| 2017-07-27 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/771856/000162828017007345/0001628280-17-007345-index.htm |
| 2017-07-28 | 10-K | Annual report [Section 13 and 15(d), not S-K Item 405] | https://www.sec.gov/Archives/edgar/data/771856/000162828017007429/0001628280-17-007429-index.htm |
| 2017-08-28 | DEF 14A | Other definitive proxy statements | https://www.sec.gov/Archives/edgar/data/771856/000162828017008952/0001628280-17-008952-index.htm |
| 2017-08-31 | DEFR14A | Revised definitive proxy soliciting materials | https://www.sec.gov/Archives/edgar/data/771856/000162828017009028/0001628280-17-009028-index.htm |
| 2017-09-14 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/771856/000162828017009310/0001628280-17-009310-index.htm |
| 2017-09-14 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/771856/000162828017009317/0001628280-17-009317-index.htm |
| 2017-10-04 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/771856/000162828017009685/0001628280-17-009685-index.htm |
| 2017-10-16 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/771856/000162828017009909/0001628280-17-009909-index.htm |
| 2017-11-13 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/771856/000162828017011455/0001628280-17-011455-index.htm |
| 2017-11-13 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/771856/000162828017011460/0001628280-17-011460-index.htm |
| 2017-11-13 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/771856/000162828017011463/0001628280-17-011463-index.htm |
| 2017-11-13 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/771856/000162828017011470/0001628280-17-011470-index.htm |
| 2017-12-07 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/771856/000162828017012191/0001628280-17-012191-index.htm |
| 2017-12-15 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/771856/000162828017012357/0001628280-17-012357-index.htm |
| 2018-03-12 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/771856/000162828018003075/0001628280-18-003075-index.htm |
| 2018-03-15 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/771856/000162828018003224/0001628280-18-003224-index.htm |
| 2018-03-19 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/771856/000162828018003346/0001628280-18-003346-index.htm |
| 2018-03-26 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/771856/000162828018003566/0001628280-18-003566-index.htm |
| 2018-03-28 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/771856/000162828018003737/0001628280-18-003737-index.htm |
| 2018-07-26 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/771856/000162828018009635/0001628280-18-009635-index.htm |
| 2018-07-30 | 10-K | Annual report [Section 13 and 15(d), not S-K Item 405] | https://www.sec.gov/Archives/edgar/data/771856/000162828018009773/0001628280-18-009773-index.htm |
| 2018-08-28 | DEF 14A | Other definitive proxy statements | https://www.sec.gov/Archives/edgar/data/771856/000162828018011478/0001628280-18-011478-index.htm |
| 2018-09-13 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/771856/000162828018011830/0001628280-18-011830-index.htm |
| 2018-09-14 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/771856/000162828018011874/0001628280-18-011874-index.htm |
| 2018-10-03 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/771856/000162828018012240/0001628280-18-012240-index.htm |
| 2018-10-05 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/771856/000162828018012338/0001628280-18-012338-index.htm |
| 2018-10-12 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/771856/000162828018012512/0001628280-18-012512-index.htm |
| 2018-10-15 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/771856/000162828018012548/0001628280-18-012548-index.htm |
| 2018-10-16 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/771856/000162828018012569/0001628280-18-012569-index.htm |
| 2018-11-05 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/771856/000162828018013555/0001628280-18-013555-index.htm |
| 2018-11-05 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/771856/000162828018013556/0001628280-18-013556-index.htm |
| 2018-11-05 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/771856/000162828018013557/0001628280-18-013557-index.htm |
| 2018-11-05 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/771856/000162828018013558/0001628280-18-013558-index.htm |
| 2018-11-05 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/771856/000162828018013559/0001628280-18-013559-index.htm |
| 2018-11-05 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/771856/000162828018013560/0001628280-18-013560-index.htm |
| 2018-11-08 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/771856/000162828018014013/0001628280-18-014013-index.htm |
| 2018-12-17 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/771856/000162828018015177/0001628280-18-015177-index.htm |
| 2018-12-17 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/771856/000162828018015187/0001628280-18-015187-index.htm |
| 2018-12-20 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/771856/000162828018015324/0001628280-18-015324-index.htm |
| 2019-01-04 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/771856/000162828019000100/0001628280-19-000100-index.htm |
| 2019-01-07 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/771856/000162828019000136/0001628280-19-000136-index.htm |
| 2019-01-16 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/771856/000162828019000359/0001628280-19-000359-index.htm |
| 2019-03-18 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/771856/000162828019003074/0001628280-19-003074-index.htm |
| 2019-03-18 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/771856/000162828019003086/0001628280-19-003086-index.htm |
| 2019-07-15 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/771856/000162828019008752/0001628280-19-008752-index.htm |
| 2019-07-29 | 10-K | Annual report [Section 13 and 15(d), not S-K Item 405] | https://www.sec.gov/Archives/edgar/data/771856/000162828019009139/0001628280-19-009139-index.htm |
| 2019-08-28 | DEF 14A | Other definitive proxy statements | https://www.sec.gov/Archives/edgar/data/771856/000162828019011252/0001628280-19-011252-index.htm |
| 2019-09-05 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/771856/000162828019011423/0001628280-19-011423-index.htm |
| 2019-09-16 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/771856/000162828019011740/0001628280-19-011740-index.htm |
| 2019-09-16 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/771856/000162828019011753/0001628280-19-011753-index.htm |
| 2019-10-16 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/771856/000162828019012310/0001628280-19-012310-index.htm |
| 2019-11-06 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/771856/000162828019013526/0001628280-19-013526-index.htm |
| 2019-11-06 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/771856/000162828019013528/0001628280-19-013528-index.htm |
| 2019-11-06 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/771856/000162828019013530/0001628280-19-013530-index.htm |
| 2019-11-06 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/771856/000162828019013531/0001628280-19-013531-index.htm |
| 2019-11-06 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/771856/000162828019013532/0001628280-19-013532-index.htm |
| 2019-11-06 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/771856/000162828019013533/0001628280-19-013533-index.htm |
| 2019-12-04 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/771856/000162828019014734/0001628280-19-014734-index.htm |
| 2019-12-16 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/771856/000162828019015102/0001628280-19-015102-index.htm |
| 2019-12-16 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/771856/000162828019015106/0001628280-19-015106-index.htm |
| 2020-01-03 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/771856/000162828020000084/0001628280-20-000084-index.htm |
| 2020-03-12 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/771856/000162828020003461/0001628280-20-003461-index.htm |
| 2020-03-16 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/771856/000162828020003637/0001628280-20-003637-index.htm |
| 2020-03-24 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/771856/000162828020003966/0001628280-20-003966-index.htm |
| 2020-03-26 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/771856/000162828020004085/0001628280-20-004085-index.htm |
| 2020-03-26 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/771856/000162828020004087/0001628280-20-004087-index.htm |
| 2020-03-30 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/771856/000162828020004374/0001628280-20-004374-index.htm |
| 2020-03-30 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/771856/000162828020004386/0001628280-20-004386-index.htm |
| 2020-07-27 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/771856/000162828020010661/0001628280-20-010661-index.htm |
| 2020-07-28 | 10-K | Annual report [Section 13 and 15(d), not S-K Item 405] | https://www.sec.gov/Archives/edgar/data/771856/000162828020010734/0001628280-20-010734-index.htm |
| 2020-08-28 | DEF 14A | Other definitive proxy statements | https://www.sec.gov/Archives/edgar/data/771856/000162828020013113/0001628280-20-013113-index.htm |
| 2020-09-11 | DEFM14A | Definitive proxy statement relating to merger or acquisition | https://www.sec.gov/Archives/edgar/data/771856/000162828020013464/0001628280-20-013464-index.htm |
| 2020-09-11 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material | https://www.sec.gov/Archives/edgar/data/771856/000162828020013466/0001628280-20-013466-index.htm |
| 2020-09-14 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/771856/000162828020013549/0001628280-20-013549-index.htm |
| 2020-09-14 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/771856/000162828020013559/0001628280-20-013559-index.htm |
| 2020-10-15 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/771856/000162828020014503/0001628280-20-014503-index.htm |
| 2020-10-21 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/771856/000162828020014644/0001628280-20-014644-index.htm |
| 2020-10-28 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/771856/000162828020014963/0001628280-20-014963-index.htm |
| 2020-11-03 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/771856/000162828020015394/0001628280-20-015394-index.htm |
| 2020-11-03 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/771856/000162828020015396/0001628280-20-015396-index.htm |
| 2020-11-03 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/771856/000162828020015400/0001628280-20-015400-index.htm |
| 2020-11-03 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/771856/000162828020015402/0001628280-20-015402-index.htm |
| 2016-12-13 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/771856/000168316816000921/0001683168-16-000921-index.htm |
| 2018-08-07 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/771856/000168316818002160/0001683168-18-002160-index.htm |
Champions Oncology, Inc (CSBR) Insider Transactions:
Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Champions Oncology, Inc (CSBR). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.Insider Ownership: 2055%Institutional Ownership: 5379%
| Transaction Date | Insider Name | Insider Title | Type | Shares Number | Shares Price | Total Transaction | Shares Held After Transaction | Link |
|---|---|---|---|---|---|---|---|---|
| 2020-10-30 | SCOTT R TOBIN | Director | Buy | 10,000.00 | 5.46 | 54,600.00 | 10,000.00 | https://www.sec.gov/Archives/edgar/data/771856/000117911020010718/0001179110-20-010718-index.htm |
| 2018-10-01 | JOEL ACKERMAN | Director | Sell | 22,535.00 | 17.02 | 383,545.70 | 1,021,731.00 | https://www.sec.gov/Archives/edgar/data/771856/000162828018012240/0001628280-18-012240-index.htm |
| 2018-03-22 | Ronnie Morris | CEO | Buy | 60.00 | 3.50 | 210.00 | 1,111,407.00 | https://www.sec.gov/Archives/edgar/data/771856/000162828018003566/0001628280-18-003566-index.htm |
| 2018-03-23 | Ronnie Morris | CEO | Buy | 440.00 | 3.50 | 1,540.00 | 1,111,847.00 | https://www.sec.gov/Archives/edgar/data/771856/000162828018003566/0001628280-18-003566-index.htm |
| 2018-03-22 | Ronnie Morris | CEO | Buy | 200.00 | 3.48 | 696.50 | 1,112,047.00 | https://www.sec.gov/Archives/edgar/data/771856/000162828018003566/0001628280-18-003566-index.htm |
| 2019-01-02 | JOEL ACKERMAN | Director | Buy | 4,167.00 | 4.80 | 20,001.60 | 1,113,877.00 | https://www.sec.gov/Archives/edgar/data/771856/000162828019000100/0001628280-19-000100-index.htm |
| 2018-03-26 | Ronnie Morris | CEO | Buy | 2,235.00 | 3.57 | 7,978.95 | 1,114,282.00 | https://www.sec.gov/Archives/edgar/data/771856/000162828018003737/0001628280-18-003737-index.htm |
| 2018-03-27 | Ronnie Morris | CEO | Buy | 2,300.00 | 3.62 | 8,319.10 | 1,116,582.00 | https://www.sec.gov/Archives/edgar/data/771856/000162828018003737/0001628280-18-003737-index.htm |
| 2018-10-12 | JOEL ACKERMAN | Director | Buy | 100,000.00 | 2.10 | 210,000.00 | 1,121,731.00 | https://www.sec.gov/Archives/edgar/data/771856/000162828018012512/0001628280-18-012512-index.htm |
| 2019-12-02 | JOEL ACKERMAN | Director | Buy | 201,590.00 | 2.10 | 423,339.00 | 1,315,467.00 | https://www.sec.gov/Archives/edgar/data/771856/000162828019014734/0001628280-19-014734-index.htm |
| 2019-12-02 | JOEL ACKERMAN | Director | Buy | 1,521.00 | 2.10 | 3,194.10 | 1,316,988.00 | https://www.sec.gov/Archives/edgar/data/771856/000162828019014734/0001628280-19-014734-index.htm |
| 2020-03-06 | New Enterprise Associates 14, L.P. | 10% Share Holder | Sell | 708,155.00 | 6.99 | 4,950,003.45 | 1,713,720.00 | https://www.sec.gov/Archives/edgar/data/771856/000120919120017699/0001209191-20-017699-index.htm |
| 2018-11-06 | Daniel Newman Mendelson | Director | Sell | 5,000.00 | 13.75 | 68,750.00 | 57,500.00 | https://www.sec.gov/Archives/edgar/data/771856/000162828018014013/0001628280-18-014013-index.htm |
| 2020-03-24 | Daniel Newman Mendelson | Director | Buy | 26.00 | 5.50 | 143.00 | 57,526.00 | https://www.sec.gov/Archives/edgar/data/771856/000162828020004087/0001628280-20-004087-index.htm |
| 2020-03-26 | Daniel Newman Mendelson | Director | Buy | 20.00 | 6.00 | 120.00 | 57,546.00 | https://www.sec.gov/Archives/edgar/data/771856/000162828020004374/0001628280-20-004374-index.htm |
| 2020-03-26 | Daniel Newman Mendelson | Director | Buy | 100.00 | 5.99 | 599.00 | 57,646.00 | https://www.sec.gov/Archives/edgar/data/771856/000162828020004374/0001628280-20-004374-index.htm |
| 2020-03-26 | Daniel Newman Mendelson | Director | Buy | 100.00 | 5.97 | 597.00 | 57,746.00 | https://www.sec.gov/Archives/edgar/data/771856/000162828020004374/0001628280-20-004374-index.htm |
| 2020-03-26 | Daniel Newman Mendelson | Director | Buy | 700.00 | 5.90 | 4,130.00 | 58,446.00 | https://www.sec.gov/Archives/edgar/data/771856/000162828020004374/0001628280-20-004374-index.htm |
| 2020-03-26 | Daniel Newman Mendelson | Director | Buy | 300.00 | 5.89 | 1,767.00 | 58,746.00 | https://www.sec.gov/Archives/edgar/data/771856/000162828020004374/0001628280-20-004374-index.htm |
| 2018-09-20 | Daniel Newman Mendelson | Director | Sell | 8,333.00 | 13.02 | 108,495.66 | 62,500.00 | https://www.sec.gov/Archives/edgar/data/771856/000162828018012338/0001628280-18-012338-index.htm |
| 2020-10-16 | DAVID SIDRANSKY | Director | Buy | 16,667.00 | 5.46 | 91,001.82 | 758,334.00 | https://www.sec.gov/Archives/edgar/data/771856/000162828020014963/0001628280-20-014963-index.htm |
| 2018-12-19 | Ronnie Morris | CEO | Buy | 20,000.00 | 7.44 | 148,800.00 | 833,001.00 | https://www.sec.gov/Archives/edgar/data/771856/000162828018015324/0001628280-18-015324-index.htm |
| 2019-01-16 | Ronnie Morris | CEO | Buy | 4,167.00 | 4.80 | 20,001.60 | 837,168.00 | https://www.sec.gov/Archives/edgar/data/771856/000162828019000359/0001628280-19-000359-index.htm |
| 2020-03-24 | Ronnie Morris | CEO | Sell | 75.00 | 5.25 | 393.75 | 837,168.00 | https://www.sec.gov/Archives/edgar/data/771856/000162828020004085/0001628280-20-004085-index.htm |